updat confirm catalyst track
report result opex provid updat outlook
key catalyst remain track karxt schizophrenia registr path updat
expect follow fda meet trial initi anticip
present addit data efficaci safeti
includ analysi trae rate adjunct set schizophrenia potenti
new indic develop path updat expect drp
data healthi elderli volunt expect experiment pain
data expect recent initi coverag view
karxt uniqu competit advantag larg market opportun
remain well-fund cash maintain outperform
fda meet remain track follow updat feedback
pivot strategi anticip initi first two trial
design like similar posit trial result demonstr
week panss score reduct pt karxt vs placebo
signific efficaci neg cognit symptom favor toler
present featur addit data efficaci
safeti includ analysi trae rel rate karxt vs placebo time-
cours incid believ addit efficaci data could includ exploratori
analys cognit benefit note competitor recent data
privat present view karxt potenti superior base faster
activ panss-scal larger effect cgi-
adjunct set schizophrenia potenti indic karxt
develop timelin updat expect previous plan
evalu drug/drug interact studi neg cognit
symptom anticip move trial flexibl dose
view rational sound base clinic practic potenti moa combin
synergi room improv market antipsychot
drp data healthi elderli volunt still expect believ
karxt demonstr improv safeti similar efficaci xanomelin
trial inform dose optim subsequ trial
meanwhil pimavanserin set drp regulatori preced snda
file expect like fda adcomm experiment pain
data expect present anoth catalyst
recent initi coverag view current share price
attract entri point ahead key catalyst believ uniqu moa karxt
enabl competit advantag schizophrenia drp cash
provid runway maintain outperform
year price histori
karuna inc clinical-
cholinerg receptor treat numer
headquart boston
juli
analyst certif import disclosur see disclosur
schziophrenia pivot result posit
success launch schizophrenia treatment set
regulatori preced drp indic
partnership ex-u commerci
better expect clinic data readout
higher estim peak sale
view leader schizophrenia neuropsychiatr
disord lead clinic develop candid karxt
receptor believ uniqu moa enabl potenti
superior current avail antipsychot view
well-capit ahead expect pivot program
karxt schizopjhrenia follow strong result
ascp present addit data
unexpect safeti signal karxt
failur clinic trial endpoint
lower expect product sale
higher anticip competit
legal challeng intellectu properti
price target base dcf valuat methodolog estim wacc believ
adequ reflect risk associ predominantli single-asset compani residu growth rate due assum
patent expir karxt estim total risk-adjust peak sale across indic
key downsid risk price target clinic develop risk regulatori risk karxt current pend pivot
develop stage addit risk aris lower-than-expect peak sale estim due higher-than-anticip competit
failur gain support medic commun healthcar prescrib third-parti payor risk relat legal
challeng patent protect karxt
exhibit agonist trial schizophrenia primari endpoint
chang panss total score baselin week demonstr chang vs
placebo separ occur week reach signific week
cohen effect size week potenti compet differenti moa
exhibit karxt agonist antagonist trial schizophrenia primari endpoint
chang panss total score baselin week karxt demonstr chang vs
placebo separ occur immedi reach signific week sustain
week week cohen effect size week despit inher limit
cross-trial comparison view karxt data support rapid activ larger effect size
exhibit demonstr cgi- score improv vs placebo week although
endpoint adjust multipl comparison assess statist signific
clearli demonstr greater efficaci panss posit neg sub-scal cgi- score
exhibit karxt demonstr statist signific cgi- improv vs placebo
also demonstr statist signific improv panss posit neg sub-scal vs
placebo separ reach time-point view karxt
potenti superior base cgi- score reflect broader versatil
exhibit dcf valuat support
discount except per-shar data revenu chang work valu growth valu rateequ valu per sharetermin valu growth rate
good
royalti ptchf
share-bas compens
total share-bas compenst
share-bas compens sg
total share-bas compenst
total share-bas compens exclud non-gaap
earn tax loss
stock price compani mention report may
compani lly-nys cover
